FINWIRES · TerminalLIVE
FINWIRES

ImmuneOnco Biopharma Doses First Patient in Phase 2/3 IgG4 Disease Trial

By

ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said the first patient has been dosed in a Phase 2/3 clinical trial of its lead drug candidate IMM0306 for the treatment of IgG4-related disease, according to a Friday Hong Kong bourse filing.

The trial will evaluate the efficacy of IMM0306 in reducing the risk of disease relapse, with secondary endpoints including safety, tolerability, pharmacokinetics and immunogenicity.

Shares of the biopharmaceutical firm were up nearly 4% in midday trade on Friday.

Related Articles

Asia

FDC Consolidated Shares Rise Nearly 4% on Second Day of Trading

FDC Consolidated Holdings (ASX:FDC) shares rose nearly 4% in recent Friday trade on the construction firm's second day of trading on the Australian bourse.The company raised AU$400.8 million in its initial public offering through the issue of about 133.6 million shares at a price of AU$3 each.

ASX:FDC
Asia

Market Chatter: No Plans to Cut Headcount Amid Rise in AI Adoption, Tata Consultancy CEO Says

Indian technology giant Tata Consultancy Services (NSE:TCS, BOM:532540) does not plan to reduce its overall headcount due to artificial intelligence (AI) and will hire for newer AI-native skill sets, according to a Moneycontrol.com report on Thursday, citing the company's chief executive officer and managing director K Krithivasan.Krithivasan's comments come amid rising concerns of job losses due to the notion that AI will replace employees.There would be no "drastic change" in headcount, however, there could be a change in the skillset requirements, and other new opportunities would come up, Krithivasan said at the company's June earnings conference on Thursday, according to the news report.In the fiscal first quarter ended June 30, Tata Consultancy Services recorded its biggest quarterly headcount addition in four years with the addition of 9,279 employees on a net basis, taking its total workforce to 593,798, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

BOM:532540NSE:TCS
Asia

Update: Sandfire Resources Advances US Copper Project With Expanded Pre-Feasibility Study, Shares Up 4%

(Update to add stock movement in the headline and the sixth paragraph)Sandfire Resources (ASX:SFR) issued an updated pre-feasibility study (PFS) for its Black Butte copper project in Montana, outlining a substantially larger development with an extended mine life and enhanced project scale, according to an Australian bourse filing on Thursday after market hours.The study reports a maiden ore reserve for the Lowry deposit of 4.7 million tonnes grading 2.1% copper, containing 100,000 tonnes of copper, alongside a 255% increase in the Lowry mineral resource to 31.5 million tonnes grading 1.3% copper, containing 400,000 tonnes of copper, per the filing.Additionally, Black Butte's total ore reserves increased by 49% to 14.3 million tonnes grading 2.6% copper, containing 370,000 tonnes of copper, extending the planned mine life by about 50% to 12 years, the filing said.The project is expected to produce 35,000 tonnes per annum of contained copper in its first four years, averaging 31,000 tonnes per annum over the initial mine life, with Johnny Lee fully permitted and Lowry advancing through approvals.The PFS is based on a long-term copper price of $4.70 per pound, with initial capital expenditure estimated at around $474 million, life-of-mine sustaining capital of $180 million, an 88% metallurgical recovery rate, and a C1 cash cost of $2.68 per pound of payable copper, the filing added.Its shares rose 4% in recent trading on Friday.

ASX:SFR